New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Adial Pharmaceuticals, Inc

Contributing Author

Recent Articles by Adial Pharmaceuticals, Inc

Oct-09	Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution ADIL GlobeNewswire
Sep-16	Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04 ADIL GlobeNewswire
Sep-03	Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule ADIL GlobeNewswire
Aug-20	Adial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder Treatments ADIL GlobeNewswire
Aug-14	Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update ADIL GlobeNewswire
Aug-06	Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting ADIL GlobeNewswire
Jul-16	Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders' Equity Listing Requirement ADIL GlobeNewswire
Jul-09	Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045 ADIL GlobeNewswire
Jun-25	Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply ADIL GlobeNewswire
Jun-17	Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering ADIL GlobeNewswire
Jun-16	Adial Pharmaceuticals Submits Briefing Package to Guide Upcoming FDA Meeting ADIL GlobeNewswire
Jun-11	Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04 ADIL GlobeNewswire
May-15	Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update ADIL GlobeNewswire
May-13	Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study ADIL GlobeNewswire
May-08	Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration ADIL GlobeNewswire
May-02	Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds ADIL GlobeNewswire
May-01	Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders ADIL GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.